¼¼°èÀÇ È£Èí±â Ä¡·á±â ½ÃÀå
Therapeutic Respiratory Devices
»óǰÄÚµå : 1659380
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 92 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ È£Èí±â Ä¡·á±â ½ÃÀåÀº 2030³â±îÁö 594¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 488¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ È£Èí±â Ä¡·á±â ½ÃÀåÀº 2024-2030³â¿¡ CAGR 3.3%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 594¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ±âµµ¾ç¾Ð µð¹ÙÀ̽º´Â CAGR 3.8%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á±îÁö 323¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ³×ºæ¶óÀÌÀú ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 3.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 131¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 5.7%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ È£Èí±â Ä¡·á±â ½ÃÀåÀº 2024³â¿¡ 131¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 120¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 5.7%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 1.7%¿Í 2.7%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ È£Èí±â Ä¡·á±â ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

È£Èí±â Ä¡·á±â´Â È£Èí±â Ä¡·á¸¦ ¾î¶»°Ô °³¼±Çϰí Àִ°¡?

È£Èí±â Ä¡·á±â´Â õ½Ä, COPD, ¼ö¸é¹«È£ÈíÁõ µî È£Èí±â Áúȯ ȯÀÚÀÇ È£ÈíÀ» µ½±â À§ÇØ °í¾ÈµÈ ÀÇ·á ÅøÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±â±â¿¡´Â ºÐ¹«±â, »ê¼Ò¹ß»ý±â, CPAP ±â°è, ÀΰøÈ£Èí±â, ÈíÀԱ⠵îÀÌ Æ÷ÇԵǸç, Ç¥ÀûÀ» ¿ÏÈ­Çϰí, »ê¼Ò ³óµµ¸¦ À¯ÁöÇϸç, ±âµµ ¾Ð·ÂÀ» Áö¿øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Àåºñ´Â ±Þ¼º±â ÀÇ·á¿Í ¸¸¼º±â ÀÇ·á ¸ðµÎ¿¡¼­ »ç¿ëµÇ¸ç, ¼Ò¾ÆºÎÅÍ ³ëÀαîÁö ´Ù¾çÇÑ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù. Àü ¼¼°è¿¡¼­ È£Èí±â ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó È£Èí±â Ä¡·á±â´Â È¿°úÀûÀÎ Ä¡·á¿Í ȯÀÚ ¿¹ÈÄ °³¼±, ƯÈ÷ ¸¸¼ºÁúȯÀÇ °ü¸®¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

È£Èí±â Ä¡·á±â ½ÃÀåÀÇ ÁÖ¿ä ºÎ¹®Àº?

Á¦Ç° À¯Çü¿¡´Â ºÐ¹«±â, ÈíÀÔ±â, ÈíÀÔ±â, CPAP Àåºñ, ÀΰøÈ£Èí±â, »ê¼Ò¹ß»ý±â µîÀÌ ÀÖ½À´Ï´Ù. ±× Áß ÈíÀÔ±â´Â õ½Ä, COPD µîÀÇ Áõ»ó °ü¸®¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¿ëµµ´Â ÀÀ±ÞÀÇ·áºÎÅÍ ÀçÅÃÀÇ·á±îÁö ´Ù¾çÇϸç, ƯÈ÷ ÀçÅÃÀÇ·á´Â ȯÀÚ°¡ ¸¸¼º È£Èí±â ÁúȯÀ» °ü¸®Çϱâ À§ÇÑ Æí¸®ÇÑ ¼Ö·ç¼ÇÀ» ¿øÇϰí ÀÖÀ¸¸ç, ±Þ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÃÖÁ¾»ç¿ëÀÚ¿¡´Â º´¿ø, Ŭ¸®´Ð, ÀçÅÃÄ¡·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ Æ÷ÇÔµÇÁö¸¸, ÁßȯÀÚ½Ç, ÀÀ±Þ½Ç, ¼ö¼ú ÈÄ È¸º¹±â¿¡ Áß¿äÇÑ È£Èí±â °ü¸®°¡ ÇÊ¿äÇϹǷΠº´¿øÀÌ °¡Àå Å« ½ÃÀåÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.

È£Èí±â Ä¡·á±â´Â ÇコÄɾ¼­ ¾î¶»°Ô »ç¿ëµÇ´Â°¡?

º´¿ø¿¡¼­´Â ÁßȯÀڽǿ¡¼­ ±Þ¼º È£ÈíºÎÀü, Æó·Å ¹× ±âŸ ½É°¢ÇÑ »óŸ¦ Ä¡·áÇÏ´Â µ¥ ÀÖÀ¸¸ç, È£Èí±â Ä¡·á±â°¡ ÇʼöÀûÀÔ´Ï´Ù. ÀΰøÈ£Èí±â¿Í CPAP Àåºñ´Â ±â°èÀû ȯ±â¸¦ ÅëÇØ »ê¼Ò °ø±Þ°ú ±âµµ ¾Ð·ÂÀ» À¯ÁöÇÕ´Ï´Ù. ÀçÅÃÄ¡·á¿¡¼­ ºÐ¹«±â¿Í »ê¼Ò¹ß»ý±â´Â ¸¸¼º È£Èí±â ÁúȯÀ» °ü¸®ÇÏ´Â µ¥ ÀÚÁÖ »ç¿ëµÇ¸ç, ȯÀÚ´Â º´¿ø¿¡ °¡Áö ¾Ê°íµµ Áö¼ÓÀûÀÎ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ¿Ü·¡ Áø·á¿¡¼­ ÈíÀÔ±â¿Í ÈÞ´ë¿ë ºÐ¹«±â´Â õ½Ä ¹ßÀÛÀ̳ª COPD°¡ ¾ÇÈ­µÉ ¶§ Áï°¢ÀûÀÎ ¿ÏÈ­¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ Àåºñ´Â È£Èí ÀçȰ¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» ÇÏ¿© Æó ±â´ÉÀÇ Àå±âÀûÀΠȸº¹°ú À¯Áö¿¡ µµ¿òÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù.

È£Èí±â Ä¡·á±â ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

È£Èí±â Ä¡·á ±â±â ½ÃÀåÀÇ ¼ºÀåÀº ¸¸¼º È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡, ±â±â ±â¼ú ¹ßÀü, ÀçÅà ġ·á ¼ö¿ä Áõ°¡ µî ¿©·¯ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ½º¸¶Æ® ÈíÀÔ±â, ÈÞ´ë¿ë »ê¼Ò¹ß»ý±â, AI ÅëÇÕ ÀΰøÈ£Èí±â µîÀÇ Çõ½ÅÀº ÀÓ»ó ¹× ÀçÅà ȯ°æ ¸ðµÎ¿¡¼­ Æø³ÐÀº äÅÃÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ȯÀÚ ¿¹ÈÄ °³¼±, ÀÔ¿ø °¨¼Ò, È¿°úÀûÀΠȣÈí °ü¸® º¸Àå¿¡ ÁßÁ¡À» µÎ°í ´Ù¾çÇÑ È£Èí±â Áúȯ¿¡ ´ëÇÑ Áß¿äÇÑ Áö¿øÀ» Á¦°øÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ Àåºñ¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ·á ÀÎÇÁ¶óÀÇ È®´ë, È£Èí±â °Ç°­¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ÀÇ·á Á¢±Ù¼º Çâ»óÀ» À§ÇÑ Á¤ºÎÀÇ ±¸»óÀº ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, È£Èí±â Ä¡·á±â´Â Çö´ë È£Èí±â Ä¡·áÀÇ Áß¿äÇÑ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç°(±âµµ¾ç¾Ð±â, ³×ºæ¶óÀÌÀú, »ê¼Ò³óÃà±â, ÀΰøÈ£Èí±â, °¡½À±â, ±âŸ Á¦Ç°) ; ±â¼ú(HEPA ÇÊÅÍ ±â¼ú, Á¤Àü±â ¿©°ú, Áß°ø»ç ¿©°ú, ¹Ì¼¼±¸Ã¼ ºÐ¸®)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÃÑ 36°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Therapeutic Respiratory Devices Market to Reach US$59.4 Billion by 2030

The global market for Therapeutic Respiratory Devices estimated at US$48.8 Billion in the year 2024, is expected to reach US$59.4 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Positive Airway Pressure Devices, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$32.3 Billion by the end of the analysis period. Growth in the Nebulizers segment is estimated at 3.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.1 Billion While China is Forecast to Grow at 5.7% CAGR

The Therapeutic Respiratory Devices market in the U.S. is estimated at US$13.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$12.0 Billion by the year 2030 trailing a CAGR of 5.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Therapeutic Respiratory Devices Market - Key Trends and Drivers Summarized

How Are Therapeutic Respiratory Devices Improving Respiratory Care?

Therapeutic respiratory devices are medical tools designed to assist breathing in patients with respiratory disorders like asthma, COPD, and sleep apnea. These devices include nebulizers, oxygen concentrators, CPAP machines, ventilators, and inhalers, providing targeted relief, maintaining oxygen levels, and supporting airway pressure. These devices are used in both acute and chronic care settings, catering to a broad range of patients, from children to the elderly. As the prevalence of respiratory diseases rises globally, therapeutic respiratory devices have become essential for effective treatment and improved patient outcomes, especially in managing chronic conditions.

What Are the Key Segments in the Therapeutic Respiratory Devices Market?

Product types include nebulizers, inhalers, CPAP devices, ventilators, and oxygen concentrators. Among these, inhalers hold the largest market share due to their widespread use in managing conditions like asthma and COPD. Applications range from emergency care to home healthcare, with home healthcare showing rapid growth as patients seek convenient solutions for managing chronic respiratory conditions. End-users include hospitals, clinics, and home healthcare providers, with hospitals being the largest segment due to the need for critical respiratory care in ICUs, emergency wards, and post-operative recovery.

How Are Therapeutic Respiratory Devices Used Across Healthcare?

In hospitals, therapeutic respiratory devices are vital for treating acute respiratory failure, pneumonia, and other critical conditions in ICUs. Ventilators and CPAP devices provide mechanical ventilation, maintaining oxygen supply and airway pressure. In home healthcare, nebulizers and oxygen concentrators are commonly used to manage chronic respiratory conditions, allowing patients to receive continuous treatment without hospital visits. In ambulatory care settings, inhalers and portable nebulizers offer immediate relief during asthma attacks or exacerbations of COPD. Additionally, these devices play an integral role in respiratory rehabilitation, supporting long-term recovery and maintenance of lung function.

What Factors Are Driving the Growth in the Therapeutic Respiratory Devices Market?

The growth in the Therapeutic Respiratory Devices market is driven by several factors, including increasing incidence of chronic respiratory diseases, advancements in device technology, and rising demand for home-based care. Innovations like smart inhalers, portable oxygen concentrators, and AI-integrated ventilators have supported broader adoption in both clinical and home settings. The focus on improving patient outcomes, reducing hospitalizations, and ensuring effective respiratory management has further fueled demand, as these devices provide critical support for various respiratory conditions. Additionally, expanding healthcare infrastructure, rising awareness about respiratory health, and government initiatives for better healthcare access have contributed to market growth, making therapeutic respiratory devices a key element of modern respiratory care.

SCOPE OF STUDY:

The report analyzes the Therapeutic Respiratory Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Positive Airway Pressure Devices, Nebulizers, Oxygen Concentrators, Ventilators, Humidifiers, Other Products); Technology (HEPA Filter Technology, Electrostatic Filtration, Hollow Fiber Filtration, Microsphere Separation)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â